Neonatal alloimmune thrombocytopenia.

Abstract

Neonatal alloimmune thrombocytopenia (NAIT) can occur when a mother is immunized against fetal platelet antigens inherited from the father. Early diagnosis and appropriate platelet transfusion therapy are essential to prevent life-threatening intracranial hemorrhage in the thrombocytopenic fetus or neonate. Five major human platelet antigen (HPA) systems are capable of causing this disorder with HPA-1a indicated most frequently. This article reviews the pathophysiology, clinical aspects, and management of NAIT. We also present our experience with treatment of neonates affected with this disorder.

• Authors: Sandra Rothenberger
• Journal: Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis (Ther Apher) Vol. 6 Issue 1 Pg. 32-5 (Feb 2002) ISSN: 1091-6660 [Print] United States
• PMID: 11886574 (Publication Type: Journal Article, Review)

Chemical References

• Antigens, Human Platelet
• Epitopes
• ITGB3 protein, human
• Integrin beta3

Topics

• Antigens, Human Platelet (immunology)
• Blood Group Incompatibility (immunology, therapy)
• Epitopes
• Female
• Humans
• Infant, Newborn
• Integrin beta3
• Platelet Transfusion
• Pregnancy
• Thrombocytopenia (immunology, therapy)